This study is currently not recruiting participants.

A Phase II Study of Pazopanib (GW786034 NSC# 737754) in Children Adolescents and Young Adults with Refractory Solid Tumors

Investigation of an Investigational Medication for Pediatric Sarcomas and Other Tumors

Not Recruiting
1 years - 18 years
All
Phase N/A

Brief description of study.

The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, non rhabdomyosarcomatous soft tissue sarcoma, Ewing sarcoma, relapsed or refractory osteosarcoma, neuroblastoma (measurable and/or evaluable), or hepatoblastoma.

Detailed description of study

The purpose of this study is to test the safety of pazopanib in children, adolescents and young adults.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Refractory Solid Tumor
  • Age: 1 years - 18 years
  • Gender: All

This study investigates the effects of an investigational medication on children, adolescents, and young adults with certain types of cancer. These cancers include rhabdomyosarcoma, non-rhabdomyosarcomatous soft tissue sarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, and hepatoblastoma. The purpose of this study is to understand how this medication affects these conditions, whether the effects are good or bad.

Participants in this study will receive the investigational medication. The study will monitor the safety of this medication in young patients, assessing its effects on their cancer and any potential side effects.

  • Who can participate: Children, adolescents, and young adults aged 12 months to 18 years with specific types of relapsed or refractory sarcoma or other tumors like neuroblastoma or hepatoblastoma may participate.
  • Study details: Participants will receive an investigational medication and be monitored for its effects on their cancer and any side effects.
Updated on 19 Feb 2024. Study ID: 1408853038 (PHO-GSK-FALLO

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team